14 March 2012, Munich, Germany – On 15 May 2012, business developers and venture capitalists will come together in Munich with leading scientists and technology transfer professionals from all over Europe for BioVaria 2012. During the event, they will learn about the top life-science inventions emanating from publicly funded research and initiate partnerships for the further development of promising projects with academic institutions and universities.
Thirteen European technology transfer offices, led by Ascenion, will host this year’s BioVaria. For the first time, a guest partner from across the Atlantic will also take part. For BioVaria 2012, they have selected the most innovative and commercially attractive technologies from the research organizations and universities they represent. Altogether, some 70 projects will be presented, mainly therapeutic and diagnostic candidates in the fields of cancer, inflammation, autoimmune disease, cardiovascular disease and other major human diseases. The corresponding lead scientist from each project will be available for discussion throughout the event.
One of the licensing opportunities that will be featured at BioVaria 2012 provides a new approach for treating chronic obstructive pulmonary disease (COPD), a devastating lung disease, for which no causal therapy exists. A research team of the Comprehensive Pneumology Center (CPC) at the Helmholtz Zentrum München discovered that the specific inhibition of a certain enzyme (GSK-3ß) attenuates emphysema and improves lung function by activating the WNT/ß-catenin signaling pathway. The approach was confirmed in relevant model systems. Various inhibitors are currently being screened.
‘BioVaria offers an unmatched density of highly attractive IP assets,’ Dr Joachim Rothe, General Partner at Life Sciences Partners (LSP), comments. ‘Moreover, participants can directly meet the technology transfer specialists and the lead scientist from each project, making BioVaria a highly efficient place for initiating partnerships.’
Further information and a preview of additional technologies that have been accepted for BioVaria 2012 are now available online at www.biovaria.org.
Early registration ends on 16 March 2012.
For registration and further information please visit <link http: www.biovaria.org>www.biovaria.org
About BioVaria
BioVaria is a pan-European, biopharmaceutical showcasing event jointly organized by Ascenion and a broad range of technology transfer organizations. For both industry and academia, it provides a unique platform to meet and initiate partnerships for the development of promising early-stage projects.
Key features of BioVaria:
• One interactive day providing a comprehensive overview of licensing and investment opportunities emanating from publicly funded research in Europe
• Focus on commercially attractive, patent-protected technologies covering research tools, diagnostic and therapeutic candidates in the fields of cancer, infectious diseases, metabolic, autoimmune and neurodegenerative disorders, and other disease areas
• Presentation of about 70 technologies
• Unique format combining 10-min oral presentations with an all-day poster exhibition
• Ample space to discuss scientific details face-to-face with the inventors
BioVaria 2012 partners:
European technology transfer partners: Ascenion GmbH, Austria Wirtschaftsservice
Gesellschaft mbH, Bayerische Patentallianz GmbH, BDC - The Business Development
Company GmbH, BTO - Bergen Teknologioverføring AS, EMBLEM Technology Transfer
GmbH, FIST S.A. (France Innovation Scientifique & Transfert), IPAL GmbH, KU
Leuven Research & Development (LRD), Max Planck Innovation GmbH, National
Genome Research Network, PROvendis GmbH, Tecnalia Research & Innovation
Guest partner from Canada: University of Manitoba’s Technology Transfer Office
(TTO)
Sponsors: BioM, Bayer Healthcare, Boehringer Ingelheim, Bachem AG, Hertin - IP
Law Firm, MSD, Novo Nordisk, Sanofi, Vossius & Partner
Media partners: Going Public Magazin, Innovaro Pharmalicensing, transkript
Communication partner: KONOCOM
